Work published by Tai and co-workers suggested that certain prostate cancers might involve higher-than-normal activity of 15-PGDH [44], and for such cases application of inhibitors based on the chemotypes identified in this study may prove useful. This evidence concerns the gene HPGD and prostate cancer.